Release Date: June 4, 2022
Expiration Date: June 29, 2022
Activity Overview
This educational activity is an archive of the live virtual presentation held on June 3, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians involved in the treatment of DLBCL.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Determine DLBCL subtypes, biomarkers, and risk assessment methods, and how these factors inform treatment strategies for patients with relapsed/refractory (R/R) disease
- Evaluate the clinical profiles of current and emerging targeted therapies investigated for the treatment of R/R DLBCL
- Implement strategies to monitor and mitigate the impact of adverse events associated with targeted therapies among patients with R/R DLBCL
- Translate treatment guidelines and landmark trial data on targeted therapies to personalize sequencing strategies for patients with R/R DLBCL
Christopher R. Flowers, MD, MS, FASCO
Division Head ad interim, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research, Celgene, Cellectis, Eastern Cooperative Oncology Group, EMD Serono, Gilead, Genentech/Roche, Guardant, Iovance, Janssen, Kite, MorphoSys, National Cancer Institute, Nektar Therapeutics, Novartis, Pfi zer, Pharmacyclics, Sanofi , Takeda, TG Therapeutics, V Foundation, Xencor, Ziopharm; Consultant: AstraZeneca, BeiGene, Bio Ascend, Bristol Myers Squibb, Celgene, Curio Science Denovo Biopharma, Epizyme/Incyte, Genentech/Roche, Genmab, MEI Pharma, MorphoSys, Pharmacyclics/ Janssen, Seagen.
Frederick L. Locke, MD
Vice Chair and Associate Member
Department of Blood and Marrow Transplant and Cellular Immunotherapy
Coleader, Immuno-Oncology Research Program
Research Director and Medical Director, Immune Cell Therapy Program
Moffi tt Cancer Center
Tampa, FL
Disclosures: Grant/Research Support: Allogene (Institutional), BlueBird Bio (Institutional), Bristol Myers Squibb (Institutional), Kite Pharma (Institutional), Leukemia and Lymphoma Society, National Cancer Institute, Novartis (Institutional); Consultant: Cowen, EcoR1 Capital LLC, Emerging Therapy Solutions, Gerson Lehrman Group (GLG); Other: Scientifi c Advisory Role: Allogene, Amgen, Bluebird Bio, Bristol Myers Squibb/Celgene, Calibr, Cellular Biomedicine Group, GammaDelta Therapeutics, lovance, Kite Pharma, Janssen, Legend Biotech, Novartis, Sana Biotechnology, Takeda, Umoja BioPharma, Wugen Patents, Royalties, Other Intellectual Property: Several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy.
Kami J. Maddocks, MD
Professor of Clinical Internal Medicine
Director, Lymphoma Research Program
Division of Hematology, Department of Internal Medicine
The James Cancer Hospital at The Ohio State University
Columbus, OH
Disclosures: Consultant: ADC Therapeutics, AstraZeneca, Beigene, Bristol Myers Squibb, Epizyme, Genentech, Incyte, Janssen, Kite Pharma, Lilly, MorphoSys, Seagen.
Laurie H. Sehn MD, MPH
Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
Associate Editor, Blood
University of British Columbia
Vancouver, British Columbia, CA
Disclosures: Grant/Research Support: Roche/Genentech, Teva; Consultant: AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead/Kite Pharma, Incyte, Merck, Roche/Genentech, Sandoz, Seagen, TG Therapeutics.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
